Antibody

Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting

Tuesday, April 13, 2021 - 7:55am

b'CAMBRIDGE, Mass., SUZHOU, China andROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company,presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.

Key Points: 
  • b'CAMBRIDGE, Mass., SUZHOU, China andROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company,presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.
  • This meeting is being held virtually from April 10-15, 2021.
  • The anti-B7H7 antibody is a novel immune-oncology antibody with potent anti-tumor activity generated using HBM\'s proprietary H2L2 Harbour Mice platform.\nBy leveraging its innovative discovery engine based on the Harbour Mice antibody platforms, HBM has built a sustained capability to deliver novel antibody therapeutics in the field of oncology and immunology.
  • Following the previously reported monoclonal antibody against a novel target CCR8, HBM now reports another first-in-class therapeutic antibody targeting a novel immune checkpoint - B7H7.

F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster

Saturday, April 10, 2021 - 2:22pm

Neil Brewis, Chief Scientific Officer at F-star Therapeutics, said: We are encouraged by the results of these latest preclinical studies of FS222, our tetravalent bispecific antibody targeting PD-L1 and CD137.

Key Points: 
  • Neil Brewis, Chief Scientific Officer at F-star Therapeutics, said: We are encouraged by the results of these latest preclinical studies of FS222, our tetravalent bispecific antibody targeting PD-L1 and CD137.
  • The early onset of activity and T cell proliferation gives us confidence that FS222 will allow for a wide range of treatment options.
  • Tetravalent binding by FS222 demonstrated optimal activity in multiple preclinical pharmacology studies, outperforming classic heterodimeric bispecific antibodies.
  • Forward-looking statements included in this communication are based on information available to F-star as of the date of this communication.

Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021

Saturday, April 10, 2021 - 1:31pm

This research was funded by a grant from the National Cancer Institute (NCI), part of the National Institutes of Health, to the Pediatric Preclinical Testing Consortium (PPTC).

Key Points: 
  • This research was funded by a grant from the National Cancer Institute (NCI), part of the National Institutes of Health, to the Pediatric Preclinical Testing Consortium (PPTC).
  • At AACR this year, we are presenting preclinical data in two new hematologic indications, showing AO-176s strong therapeutic potential in lymphoma and pediatric T-ALL, said Daniel Pereira, Ph.D., Chief Scientific Officer of Arch Oncology.
  • Poster Presentation Title: AO-176, a highly differentiated clinical stage anti-CD47 antibody, is efficacious in pre-clinical models of lymphoma (Abstract #954)
    AO-176 is a humanized anti-CD47 IgG2 antibody with a potential best-in-class profile.
  • In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer.

Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting

Saturday, April 10, 2021 - 1:30pm

We continue to exploit these approaches along with our bispecific, antibody-drug conjugate, and immunomodulatory platforms to build a diverse therapeutic pipeline.

Key Points: 
  • We continue to exploit these approaches along with our bispecific, antibody-drug conjugate, and immunomodulatory platforms to build a diverse therapeutic pipeline.
  • Zanidatamab is a bispecific antibody, based on Zymeworks Azymetric platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding.
  • Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
  • Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas.

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021

Saturday, April 10, 2021 - 1:30pm

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.
  • "In 2021, we anticipate submitting an IND for XmAb819, our lead XmAb 2+1 CD3 bispecific antibody targeting ENPP3, and initiating a Phase 1 study in early 2022.
  • Xencor engineered PD-L1 x CD28 bispecific antibodies to provide conditional co-stimulation of T cells, activating them when bound to tumor cells.
  • A PD-L1 x CD28 bispecific antibody, therefore, may promote CD28 co-stimulation and simultaneously block CD28's suppression by PD-L1.

US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight to 2026: Insight on FDA Approved 57 Cancer Antibodies Available in the US Market

Friday, April 9, 2021 - 2:15pm

DUBLIN, April 9, 2021 /PRNewswire/ -- The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 9, 2021 /PRNewswire/ -- The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • Cancer antibodies have helped the researchers in leaning the entire cancer therapeutics market towards a great transition i.e.
  • In the US, technology advancement is also considered a democratizing force for boosting the market paradigm for cancer-antibody drug market.
  • US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026
    US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026
    Insight On Clinical Trials by Company, Indication, Patient Segment & Phase
    US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026
    9.

Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021

Friday, April 9, 2021 - 1:00pm

Details are as follows:

Key Points: 
  • Details are as follows:
    Title of Presentation:Targeting SIRP with APX701, a Novel Myeloid Checkpoint Inhibitor (Abstract ID LB177)
    The posters will be available on the e-poster website from at 8:30 am EDT on April 10, 2021, through June 21, 2021.
  • APX005M and Apexigen's other programs were discovered using Apexigen's proprietary APXiMAB discovery platform.
  • This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies.
  • Seven product or product candidates discovered using APXiMAB are currently commercially available or in clinical development, either internally by Apexigen or by its licensees.

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Thursday, April 8, 2021 - 1:02pm

In contrast, Talem has developed the TATX-112 antibodies with the goal of specifically blocking the interaction between the target and its ligand, e.g.

Key Points: 
  • In contrast, Talem has developed the TATX-112 antibodies with the goal of specifically blocking the interaction between the target and its ligand, e.g.
  • That higher specificity is expected to increase the therapeutic window by lowering the potential risk of side effects and positively impacting treatment efficacy.
  • Additionally, the targets expression profile makes this membrane protein a promising candidate for antibody-drug conjugate-based therapies.
  • Alzheimers and other neurodegenerative diseases are associated with reduced expression levels of the target and impaired receptor signaling.

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

Wednesday, April 7, 2021 - 1:00pm

The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.

Key Points: 
  • The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.
  • In particular, the claims of the patent are directed to compositions comprising LAG525 and spartalizumab, an anti-PD-1 antibody molecule, and related methods of use of the combination in the treatment of cancer.
  • The patent is co-owned by Novartis AG and Immutep S.A.S.
  • IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.)

Atreca to Present at Upcoming Virtual Investor Conferences

Tuesday, April 6, 2021 - 9:30pm

An archived replay will be available on the company's website for 90 days following the live presentation.

Key Points: 
  • An archived replay will be available on the company's website for 90 days following the live presentation.
  • Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform.
  • These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101.
  • These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts.